Evidence map›Paper›PMID 39823329›Full record

ArticleScience advances2025

Biologically relevant integration of transcriptomics profiles from cancer cell lines, patient-derived xenografts, and clinical tumors using deep learning.

Slavica Dimitrieva, Rens Janssens, Gang Li, Artur Szalata, Rajaraman Gopalakrishnan, Chintan Parmar, Audrey Kauffmann, Eric Y Durand

Abstract read
In one paragraph

Article in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Slavica DimitrievaDisease Area Oncology, Novartis Institutes for Biomedical Research, CH-4002 Basel, Switzerland.ORCID 0000-0002-0043-2677
Rens JanssensDisease Area Oncology, Novartis Institutes for Biomedical Research, CH-4002 Basel, Switzerland.ORCID 0000-0001-5717-0340
Gang LiDisease Area Oncology, Novartis Institutes for Biomedical Research, CH-4002 Basel, Switzerland.ORCID 0000-0001-6778-2842
Artur SzalataDisease Area Oncology, Novartis Institutes for Biomedical Research, CH-4002 Basel, Switzerland.ORCID 0000-0001-8413-234X
Rajaraman GopalakrishnanDisease Area Oncology, Novartis Institutes for Biomedical Research, Cambridge, MA, USA.
Chintan ParmarDisease Area Oncology, Novartis Institutes for Biomedical Research, Cambridge, MA, USA.ORCID 0000-0002-2140-814X
Audrey KauffmannDisease Area Oncology, Novartis Institutes for Biomedical Research, CH-4002 Basel, Switzerland.
Eric Y DurandDisease Area Oncology, Novartis Institutes for Biomedical Research, CH-4002 Basel, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cell lines and patient-derived xenografts are essential to cancer research; however, the results derived from such models often lack clinical translatability, as they do not fully recapitulate the complex cancer biology. Identifying preclinical models that sufficiently resemble the biological characteristics of clinical tumors across different cancers is critically important. Here, we developed MOBER, Multi-Origin Batch Effect Remover method, to simultaneously extract biologically meaningful embeddings while removing confounder information. Applying MOBER on 932 cancer cell lines, 434 patient-derived tumor xenografts, and 11,159 clinical tumors, we identified preclinical models with greatest transcriptional fidelity to clinical tumors and models that are transcriptionally unrepresentative of their respective clinical tumors. MOBER allows for transformation of transcriptional profiles of preclinical models to resemble the ones of clinical tumors and, therefore, can be used to improve the clinical translation of insights gained from preclinical models. MOBER is a versatile batch effect removal method applicable to diverse transcriptomic datasets, enabling integration of multiple datasets simultaneously.

Indexed as

Deep LearningGene Expression ProfilingNeoplasmsTranscriptomeAnimalsCell Line, TumorGene Expression Regulation, NeoplasticHeterograftsHumansMiceXenograft Model Antitumor Assays

Identifiers

PMID39823329
PMCPMC11740957

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.